- Title
- LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
- Creators
- Susana Banerjee - Royal Marsden NHS Foundation TrustCarol Aghajanian - Memorial Sloan Kettering Cancer CenterEls Van Nieuwenhuysen - University Hospitals Leuven, Leuven Cance Institute, BGOG, Leuven, BelgiumAlessandro Santin - Yale School of MedicineKari Ring - University of VirginiaNicoletta Colombo - MylanPremal Thaker - Washington University in St. Louis School of MedicineEmily Prendergast - Minnesota OncologyKathleen Moore - University of Oklahoma Health Sciences CenterHye Sook Chon - Moffitt Cancer CenterAndrew Clamp - University of ManchesterDavid O’malley - The Ohio State UniversityBradley Monk - Florida Cancer Specialists, West Palm Beach, FL, United States of AmericaAlfonso Cortés-Salgado - Medical Oncology Department, Hospital Ramón y Cajal, Ramón y Cajal Health Research Institute (IRYCIS), Ramón y Cajal University Hospital, GEICO, Madrid, SpainMichel Fabbro - ICM Val d’Aurelle Parc Euromedecine, Oncologie Médicale, Montpellier, GINECO, Paris, FranceElsa Kalbacher - Charmo UniversityToon Van Gorp - University Hospitals Leuven, Leuven Cance Institute, BGOG, Leuven, BelgiumStephanie Lustgarten - VerastemHagop Youssoufian - VerastemRachel Grisham - Memorial Sloan Kettering Cancer Center
- Publication Details
- International journal of gynecological cancer, Vol.34, pp.A13-A13
- Publisher
- Elsevier Inc
- Identifiers
- 991006133435802656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
International journal of gynecological cancer, Vol.34, pp.A13-A13
10/2024
Metrics
2 Record Views